realtalkms.com/482 Can an MRI show whether damaged myelin is being repaired? Researchers are using an MRI technique to detect remyelination in people with MS—a potentially important step in evaluating future treatments.
We're sharing the details on RealTalk MS.
#RealTalkMS#MSResearch#MultipleSclerosis
realtalkms.com/482 A workplace accommodation doesn't have to be a major change. Sometimes a small adjustment makes all the difference. Former Microsoft HR VP Chuck Edward talks MS, disclosure, and micro-accommodations on RealTalk MS.🎧
#RealTalkMS#DisabilityInclusion#MultipleSclerosis
realtalkms.com/482 Your doctor prescribes an MS treatment, but your insurer denies it. Now AI tools can help you challenge that decision. We're sharing an AI toolbox to help you navigate insurance denials on RealTalk MS.
#MultipleSclerosis#RealTalkMS
realtalkms.com/482 He spent 30 years in HR, including serving as a Microsoft VP. But when Chuck Edward was diagnosed with MS, he kept it secret at work. Find out why and what he would do differently on RealTalk MS.
#MultipleSclerosis#RealTalkMS
realtalkms.com/481 This week on RealTalk MS:
🧠 Rethinking how we describe MS
🔬 Encouraging non-active SPMS trial results
⚠️ Why AI chatbots shouldn't practice medicine
Three important stories. One episode.
🎧 Listen now!
#RealTalkMS#MultipleSclerosis
realtalkms.com/481 We're sharing a very sad story that should remind all of us that AI chatbots like ChatGPT shouldn't be practicing medicine on RealTalk MS.
🎧Listen now on our app, available on the Apple App Store and Google Play!
#MultipleSclerosis#RealTalkMS
realtalkms.com/481 Updating the words we use for MS isn’t just about changing terminology.
It’s about improving research, helping people get the right treatment, and ensuring care reflects what’s really happening in MS.
We’re talking about it with Dr. Peter Calabresi on RealTalk MS.
#MultipleSclerosis#RealTalkMS#MSToronto2026
realtalkms.com/481 For people living with progressive MS, there are limited treatment options.
We're sharing encouraging trial results for non-active SPMS on RealTalk MS. 🎧
#MultipleSclerosis#RealTalkMS
realtalkms.com/481 The future of MS treatment could depend on asking better questions about what’s really happening in the disease. Dr. Peter Calabresi joins us to talk about how biological disease course descriptors could help us move past outdated categories and get closer to real progress on RealTalk MS.
#RealTalkMS#MultipleSclerosis#MSResearch#MSToronto2026
realtalkms.com/481 What if we made treatment decisions based on what’s really happening in the biology of MS, instead of just the label someone’s been given?
Dr. Peter Calabresi discusses what that future could look like on RealTalk MS.
#RealTalkMS#MultipleSclerosis#MSToronto2026
realtalkms.com/481 MS doesn’t always fit into a neat clinical category. People living with MS know that better than anyone. We’re talking about why updating the language we use for MS matters on RealTalk MS.
#RealTalkMS#MultipleSclerosis
realtalkms.com/481 AI can generate medical information. That doesn't mean it can safely practice medicine.
We’re sharing a tragic story that’s an important reminder: chatbots are no substitute for real medical care.
#RealTalkMS#MultipleSclerosis
realtalkms.com/481 Encouraging news for people living with non-active secondary progressive MS! 🔬
We’re sharing promising clinical trial results for people with non-active secondary progressive MS, a group that still has too few treatment options.
Listen on our new FREE app for iOS and Android, or on your favorite podcast platform today!
#RealTalkMS#MultipleSclerosis#ProgressiveMS
realtalkms.com/481 Two people with the same MS diagnosis may have very different disease activity and progression. So why are we still relying on broad clinical labels that don’t capture what’s really happening?
Dr. Peter Calabresi explores the case for biological disease course descriptors on RealTalk MS. 🎧
#RealTalkMS#MultipleSclerosis#MSToronto2026
realtalkms.com/481 Relapsing-remitting. Secondary Progressive. Primary Progressive.
We all know these labels, but do they really tell the whole story?
Dr. Peter Calabresi explains why understanding the biology of MS could change treatment decisions, research, and the future of personalized care on RealTalk MS.
#MultipleSclerosis#RealTalkMS#MSToronto2026@UVMResearch@UVMLarnerMed